Fragmentation in the US healthcare system hinders implementation of efficient workflows when it comes to real-world data, said Viraj Narayanan, MBA, vice president of Life Sciences at COTA Healthcare.
Fragmentation in the US healthcare system hinders implementation of efficient workflows when it comes to real-world data, said Viraj Narayanan, MBA, vice president of Life Sciences at COTA Healthcare.
Transcript:
COTA presented research at ASH on the challenges of abstracting data from disparate EHR systems. What was being looked at and what did COTA find?
This was a collaboration that COTA did with the Multiple Myeloma Research Foundation. Essentially what we were trying to do was go direct to providers, on a patient by patient basis, to obtain EMR records. What we found through this process was essentially the operational workflow of trying to go to individual provider site to individual provider site, and individual patient to individual patient was pretty cumbersome and time consuming. Essentially, there is a lot of administration lag, there is financial lag, to actually operationalizing that process of workflow, which speaks to a lot of the fragmentation that is the reality of the US healthcare system, at least today.
What are some of the ways the challenges of using data from disparate EHR systems can be overcome?
For better or worse, the structural underpinnings of the US healthcare system is very fragmented. You've got providers that are consolidating today as a trend, but they're still super fragmented. You've got payers, who are playing a big role in having relevant data. Then you've got an increasing number of new sources like Apple Watch, where patients are starting to hold data and becoming more empowered to hold data. But at the end of the day, unfortunately, most of the relevant clinical information is still with providers and with payers. That is going to be where partnerships have to be formed, at least in the status quo, to build consortiums of relevant data across multiple different sources.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More